home
顺序
主题
题目
日子
36
Elevar therapeutics and Neopharma establish a JV for the commercialization of Rivoceranib
admin
2019.09.26
35
Elevar Therapeutics announces ANGEL Trial Podium Presentation at ESMO
admin
2019.09.20
34
FDA approves HLB's phase 1b/2 clinical trial for Colorectal Cancer
admin
2019.08.26
33
FDA approves HLB's phase 2 clinical trial for Adenoid Cystic Carcinoma
admin
2019.08.22
32
HLB Completes application for Pre-NDA Meeting with FDA
admin
2019.08.19
31
LSK BioPharma and Jiangsu Hengrui Medicine announce enrollment of the first patient in a phase 3 clinical study
admin
2019.06.30
30
LSK BioPharma announces preliminary review of top-line results from ANGEL study
admin
2019.06.27
29
HLB to merge with US anticancer drug company LSK BioPharma
admin
2019.06.13
28
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE FDA CLEARANCE TO INITIATE A PHASE 3 CLINICAL TRIAL IN ADVANCED HEPATOCELLUL
admin
 
27
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster of Rivoceranib AM107 Study
admin